Biotechnology News and Research

RSS

Scientists reveal how TREX proteins act as passport for transfer of cell blueprints

Decoded process could hold the key to future treatments for a wide range of chronic health problems including Motor Neuron Disease, myotonic dystrophy and a wide range of cancers, University of Sheffield scientists have revealed.

16 Aug 2012

Proteonomix receives FDA approval to commence UMK-121 Phase 1 trial in end-stage liver disease

Proteonomix, Inc., a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced that the U.S. Food and Drug Administration (FDA) has granted permission to the Company to initiate a Phase 1 clinical trial with its mobilization technology UMK-121.

15 Aug 2012

NICE guidelines for diabetes prevention welcomed by EKF Diagnostics

EKF Diagnostics welcomes the recent release of a public health guidance document1 to prevent the development of type 2 diabetes in high risk individuals.

From EKF Diagnostics 15 Aug 2012

FDA requests Biovest to conduct second Phase III trial of BV301 for NHL

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that it conducted a formal clinical guidance meeting with the U.S. FDA to determine the most expeditious U.S. registration pathway for BiovaxID, its personalized cancer vaccine for the consolidation treatment of follicular non-Hodgkin's lymphoma.

15 Aug 2012

Spectrum Pharmaceuticals initiates enrollment in Phase 2b ozarelix study for prostate cancer

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced initiation of patient enrollment in the second part of the Company's randomized Phase 2 clinical program of ozarelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, in men with prostate cancer for whom hormonal treatment is indicated.

15 Aug 2012

New class of drugs may prove useful in treating cancer and aging-associated disorders

In a study published in the Proceedings of the National Academy of Sciences (PNAS) on Aug. 6, an international team led by Igor Roninson, of the University of South Carolina and the Medical University of South Carolina, reported the development of a new class of drugs that may prove useful in the treatment of cancer and aging-associated disorders.

14 Aug 2012

FDA accepts Teva's NDA for Quartette oral contraceptive

Teva Women's Health, Inc., a U.S.-based subsidiary of Teva Pharmaceutical Industries Ltd., today announced that the U.S. Food and Drug Administration has accepted for filing its New Drug Application for Quartette (levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets).

13 Aug 2012

Prestigious $2.5M NIH grant to continue work into creation of artificial salivary glands

A research team at the Helen F. Graham Cancer Center at Christiana Care Health System and the Center for Translational Cancer Research performs a key role in a prestigious National Institutes of Health research project grant of $2.5 million to continue groundbreaking work into the creation of artificial salivary glands.

13 Aug 2012

New class of polymers resistant to bacterial attachment

Using state-of-the-art technology scientists at The University of Nottingham have discovered a new class of polymers that are resistant to bacterial attachment. These new materials could lead to a significant reduction in hospital infections and medical device failures.

13 Aug 2012

Positive results from Acorda post-marketing commitment study of dalfampridine-ER for MS

Acorda Therapeutics, Inc. today announced top line results from a post-marketing commitment study evaluating a 5mg dose of dalfampridine-ER to improve walking in people with multiple sclerosis. The study failed to confirm efficacy of the 5mg dose.

13 Aug 2012

NIH awards ADi Phase II SBIR grant to scan Plasmodium falciparum proteome for protective antigens

Antigen Discovery, Inc. today announced that it has received a Phase II Small Business Innovation and Research award from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The three-year award, totaling approximately $ 2.5 million, is a continuation of a Phase I SBIR grant to scan the Plasmodium falciparum proteome for protective antigens.

13 Aug 2012

Scientists discover new class of polymers that are resistant to bacterial attachment

13 Aug 2012

Medical ethics: an interview with Anita Silvers

Medical ethics assists healthcare professionals to make decisions respectful of persons who happen to be their patients.

13 Aug 2012

Genentech receives FDA approval for Lucentis to treat diabetic macular edema

Genentech, a member of the Roche Group, today announced that Lucentis (ranibizumab injection) was approved by the U.S. Food & Drug Administration (FDA) for treatment of diabetic macular edema (DME), an eye condition in people with diabetes that causes blurred vision, severe vision loss and sometimes blindness

12 Aug 2012

Novel model may allow clinicians to predict potential for recovery after SCI

For more than 1 million people in the U.S. living with spinal cord injury, the frightening days and weeks following the injury are filled with uncertainty about their potential for recovery and future independence. A new model based on motor scores at admission and early imaging studies may allow clinicians to predict functional outcomes and guide decision-making for therapy and care-giving needs, as described in an article published in Journal of Neurotrauma, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

9 Aug 2012

Active Biotech, Teva to commence third Phase III study of laquinimod for RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech provided today an update on the clinical development program of once-daily oral laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS).

9 Aug 2012

Amgen announces decision to stop ganitumab Phase 3 trial in advanced pancreatic cancer

Amgen today announced a decision to stop the ganitumab (AMG 479) Phase 3 GAMMA (Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas) trial following the recommendation of an independent Data Monitoring Committee (DMC) overseeing the trial.

9 Aug 2012

Biotechnology News and Research

Scientists reveal how TREX proteins act as passport for transfer of cell blueprints

Proteonomix receives FDA approval to commence UMK-121 Phase 1 trial in end-stage liver disease

NICE guidelines for diabetes prevention welcomed by EKF Diagnostics

FDA requests Biovest to conduct second Phase III trial of BV301 for NHL

Spectrum Pharmaceuticals initiates enrollment in Phase 2b ozarelix study for prostate cancer

New class of drugs may prove useful in treating cancer and aging-associated disorders

FDA accepts Teva's NDA for Quartette oral contraceptive

Prestigious $2.5M NIH grant to continue work into creation of artificial salivary glands

New class of polymers resistant to bacterial attachment

Positive results from Acorda post-marketing commitment study of dalfampridine-ER for MS

NIH awards ADi Phase II SBIR grant to scan Plasmodium falciparum proteome for protective antigens

Scientists discover new class of polymers that are resistant to bacterial attachment

Medical ethics: an interview with Anita Silvers

Genentech receives FDA approval for Lucentis to treat diabetic macular edema

Novel model may allow clinicians to predict potential for recovery after SCI

Active Biotech, Teva to commence third Phase III study of laquinimod for RRMS

Amgen announces decision to stop ganitumab Phase 3 trial in advanced pancreatic cancer

PAREXEL board approves stock repurchase program

APCER Pharma updates and enhances its website

Global market value of Alzheimer's disease therapeutics could soar to $8 billion: GEN

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News